ZSAN Zosano Pharma Corporation

1.50
+0  (0%)
Previous Close 1.50
Open 1.50
Price To book 5.62
Market Cap 29.18M
Shares 19,450,000
Volume 335,492
Short Ratio 0.44
Av. Daily Volume 3,735,360

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial data due released February 13, 2017 - primary endpoints met.
M207
Migraine
Phase 2 data released September 2015. Considering Phase 3 initiation in 2016
ZP-Glucagon
Severe hypoglycemia